124 related articles for article (PubMed ID: 25637063)
1. Methodological approach to brain-derived neurotrophic factor plasma levels in major depressed patients receiving duloxetine.
Agilli M; Aydin FN
Neurol Sci; 2015 Jun; 36(6):1061-2. PubMed ID: 25637063
[No Abstract] [Full Text] [Related]
2. BDNF plasma levels variations in major depressed patients receiving duloxetine.
Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
[TBL] [Abstract][Full Text] [Related]
3. Improved Alertness Is Associated with Early Increase in Serum Brain-Derived Neurotrophic Factor and Antidepressant Treatment Outcome in Major Depression.
Mikoteit T; Hemmeter U; Eckert A; Brand S; Bischof R; Delini-Stula A; Holsboer-Trachsler E; Beck J
Neuropsychobiology; 2015; 72(1):16-28. PubMed ID: 26337518
[TBL] [Abstract][Full Text] [Related]
4. Serum brain-derived neurotrophic factor levels at 6 months after remission are not associated with subsequent depressive episodes.
Yoshimura R; Hori H; Sugita-Ikenouchi A; Umene-Nakano W; Katsuki A; Nakamura J
J Clin Psychopharmacol; 2013 Feb; 33(1):142-3. PubMed ID: 23288242
[No Abstract] [Full Text] [Related]
5. Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.
Maciukiewicz M; Marshe VS; Tiwari AK; Fonseka TM; Freeman N; Rotzinger S; Foster JA; Kennedy JL; Kennedy SH; Müller DJ
Pharmacogenomics; 2015 Nov; 16(17):1919-29. PubMed ID: 26556688
[TBL] [Abstract][Full Text] [Related]
6. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments.
Piccinni A; Marazziti D; Catena M; Domenici L; Del Debbio A; Bianchi C; Mannari C; Martini C; Da Pozzo E; Schiavi E; Mariotti A; Roncaglia I; Palla A; Consoli G; Giovannini L; Massimetti G; Dell'Osso L
J Affect Disord; 2008 Jan; 105(1-3):279-83. PubMed ID: 17553570
[TBL] [Abstract][Full Text] [Related]
7. Serum Brain-Derived Neurotrophic Factors in Taiwanese Patients with Drug-Naïve First-Episode Major Depressive Disorder: Effects of Antidepressants.
Chiou YJ; Huang TL
Int J Neuropsychopharmacol; 2017 Mar; 20(3):213-218. PubMed ID: 27811136
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
9. Restless legs syndrome associated with the combined use of duloxetine plus paroxetine.
Nikolaou KN; Michopoulos I; Douzenis A; Papazahos C; Papageorgiou C; Gournellis R
J Clin Psychopharmacol; 2015 Jun; 35(3):345-6. PubMed ID: 25815756
[No Abstract] [Full Text] [Related]
10. [The neurotrophic hypothesis of depression].
Bus BA; Molendijk ML
Tijdschr Psychiatr; 2016; 58(3):215-22. PubMed ID: 26979853
[TBL] [Abstract][Full Text] [Related]
11. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
12. Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder.
Baek JH; Kang ES; Fava M; Mischoulon D; Nierenberg AA; Lee D; Heo JY; Jeon HJ
J Affect Disord; 2014 Dec; 169():112-7. PubMed ID: 25189990
[TBL] [Abstract][Full Text] [Related]
13. Response to duloxetine in a depressed, treatment-resistant adolescent female.
Delgado SV; Saldaña SN; Barzman DH; Coffey B
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):889-94. PubMed ID: 18315460
[No Abstract] [Full Text] [Related]
14. Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants.
Ricken R; Adli M; Lange C; Krusche E; Stamm TJ; Gaus S; Koehler S; Nase S; Bschor T; Richter C; Steinacher B; Heinz A; Rapp MA; Borgwardt S; Hellweg R; Lang UE
J Clin Psychopharmacol; 2013 Dec; 33(6):806-9. PubMed ID: 24018547
[TBL] [Abstract][Full Text] [Related]
15. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine fights major depressive disorder.
Wimett L; Laustsen G
Nurse Pract; 2005 Mar; 30(3):6-7. PubMed ID: 15753808
[No Abstract] [Full Text] [Related]
17. Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment.
Deuschle M; Gilles M; Scharnholz B; Lederbogen F; Lang UE; Hellweg R
Pharmacopsychiatry; 2013 Mar; 46(2):54-8. PubMed ID: 22961097
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of BDNF expression according to antidepressant response.
Lopez JP; Mamdani F; Labonte B; Beaulieu MM; Yang JP; Berlim MT; Ernst C; Turecki G
Mol Psychiatry; 2013 Apr; 18(4):398-9. PubMed ID: 22547115
[No Abstract] [Full Text] [Related]
20. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
